Immunotherapy for Uveal Melanoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Uveal MelanomaImmunotherapy - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new immunotherapy treatment for cancer that includes two drugs and radiation therapy.

Eligible Conditions
  • Uveal Melanoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Overall survival
Progression-free survival
Response rate
safety and tolerability of the therapy

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Omalizumab
20%Injection site reaction
14%Injection site erythema
14%Injection site pruritus
14%Upper respiratory tract infection
12%Nasopharyngitis
10%Injection site swelling
6%Injection site induration
6%Injection site urticaria
5%Headache
5%Pruritus
5%Sinusitis
4%Cough
2%Viral upper respiratory tract infection
1%Asthma
1%Rectal cancer
1%Cellulitis staphylococcal
1%Sexual abuse
1%Abortion induced
This histogram enumerates side effects from a completed 2008 Phase 4 trial (NCT00267202) in the Omalizumab ARM group. Side effects include: Injection site reaction with 20%, Injection site erythema with 14%, Injection site pruritus with 14%, Upper respiratory tract infection with 14%, Nasopharyngitis with 12%.

Trial Design

1 Treatment Group

one arm
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Immunotherapy · No Placebo Group · Phase 2

one armExperimental Group · 2 Interventions: stereotactic body radiotherapy, Immunotherapy · Intervention Types: Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic body radiotherapy
2016
Completed Phase 4
~140
Immunotherapy
2016
Completed Phase 4
~1020

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

California Pacific Medical Center Research InstituteLead Sponsor
41 Previous Clinical Trials
11,636 Total Patients Enrolled
David R Minor, MDStudy ChairCalifornia Pacific Med Center Research Inst.
2 Previous Clinical Trials
36 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have no performance status.
You have no active hepatitis B.